DESCRIPTION (provided by applicant): The ability to amplify and subsequent detection a target sequence with a limited length may satisfy the need for diagnosing some of the diseases. Nevertheless, much biomedical research, such as cloning genes and analysis of genetics variation, often demands… More

DESCRIPTION (provided by applicant): Nucleic acid based diagnostic devices allow accurate identification of biological agents by specifically amplifying specific target sequences from environmental samples. Current diagnostic tests rely on PCR, a more costly and time-consuming detection method that… More

DESCRIPTION (provided by applicant): Amplification and detection of specific target sequences from DMA and RNA is a fundamental tool for diagnostics and biomedical research. We have devised a new isothermal DMA amplification method which can be used to amplify circular DMA molecules, by mimicking… More

DESCRIPTION (provided by applicant): Molecular diagnostic tests that rely on the amplification of specific sequences to identify genes of interest frequently use the polymerase chain reaction (PCR). To perform PCR, sensitive and, often, expensive instrumentation is required for thermocycling, which… More

DESCRIPTION (provided by applicant): Aside for a vast minority of asymptomatic patients diagnosed incidentally, virtually all lung cancer patients are symptomatic at presentation. As a result only 30-35% of patients have sufficiently localized tumo rs to allow for surgical resection of the… More

DESCRIPTION (provided by applicant): BioHelix is the exclusive licensee for the commercialization of a novel, primase- based Whole Genome Amplification (pWGA) technology invented by Drs. Stanley Tabor and Charles Richardson at Harvard Medical School. This pWGA system utilizes multiple replication… More

DESCRIPTION (provided by applicant): Streptococcus agalactiae, a.k.a. group B streptococcus (GBS), is one of the leading causes of morbidity, and mortality among newborns. We propose to develop a molecular assay for GBS using our proprietary helicase depe ndent amplification (HDA), and a lateral… More

DESCRIPTION (provided by applicant): BioHelix is the exclusive licensee for a novel, primase-based Whole Genome Amplification (pWGA) technology invented by Drs. Stanley Tabor and Charles Richardson at Harvard Medical School. This pWGA system utilizes multi ple replication proteins including a… More

DESCRIPTION (provided by applicant): The objective of our NIAID Biodefense Phase I SBIR program was to develop, and commercialize field deployable nucleic acid analysis devices for use in biodefense applications. We have begun to sell IsoAmp II kits that will allow our clients to develop home brew… More

This proposal seeks to develop a simple, and sensitive molecular diagnostic assay for the detection of Streptococcus equi; the causative agent of strangles. Outbreaks of this disease at racetracks and training establishments caused major disruptions, and economic losses to owners, and trainers in… More

DESCRIPTION (provided by applicant): On August 16, 2007, the FDA updated the label for warfarin to include information in the precautions section to remind physicians that people with variations in the CYP2C9 and VKORC1genes may require a lower initial d ose of the drug (see… More

DESCRIPTION (provided by applicant): We propose to develop a rapid, low cost, threshold assay for the detection of HIV infection of HIV vaccination trial participants. Infection by HIV, and viral load are the usual end points for Phase III HIV vaccination trials. Ongoing Phase III HIV vaccine… More

DESCRIPTION (provided by applicant): We propose to develop a rapid, low cost, threshold assay for the detection of HIV infection of HIV vaccination trial participants. The assay we propose to develop will use our proprietary helicase dependent amplificatio n (HDA) platform as well as a low cost… More

DESCRIPTION (provided by applicant): We propose to develop a near patient assays to score 2 SNPs associated with abacavir-severe cutaneous adverse reactions (SCAR); i.e., HLA B*5701 and the Hsp70-Hom M493T allele (a.k.a. rs2227956CT). Nucleic acid template s will be isolated from cells obtained from… More

DESCRIPTION (provided by applicant): This SBIR-AT-NIAID Phase I application addresses the problem of malaria diagnostics in resource- limited settings. BioHelix, has developed an isothermal nucleic acid amplification chemistry called helicase dependent amp lification (HDA) that is tolerant of the… More

DESCRIPTION (provided by applicant): This STTR-AT-NIAID seeks to develop an integrated nucleic acid system based on research done by Catherine Klapperich's laboratory at Boston University. The BU lab-on-a-chip includes a micro solid phase extraction (lt SPE) column, flap valves and hydrophobic… More

DESCRIPTION (provided by applicant): In this Phase I project, we propose to investigate a novel primer chemistry and probe detection system called the Zip nucleic acids (ZNA ). ZNAs are oligonucleotides conjugated to a number of cationic spermine moietiesthat enhance the effective concentration of… More